Our study evaluated baseline PIV and PILE of ES-SCLC patients treated with anti-PD-1/PD-L1 inhibitor combined with chemotherapy, aiming to find out easy-to-use biomarkers. This evidence concerns the gene CD274 and small cell lung carcinoma.